Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745387 | 0.88 | KEAP1 (0.53) | ALDH1A1KEAP1NFE2L2DHODHTP53 | |
| SCHEMBL21543189 | 0.88 | KEAP1 (0.53) | ALDH1A1KEAP1NFE2L2DHODHTP53 | |
| SCHEMBL21543168 | 0.87 | NPC1 (0.46) | DHODHMAPTNPC1RAB9AROCK2 | |
| SCHEMBL29469242 | 0.87 | NPC1 (0.46) | DHODHMAPTNPC1RAB9AROCK2 | |
| SCHEMBL21542579 | 0.78 | NPC1 (0.45) | ALDH1A1KEAP1NFE2L2DHODHTP53 | |
| SCHEMBL26708512 | 0.78 | KEAP1 (0.58) | ALDH1A1KEAP1NFE2L2DHODHEIF4E | |
| SCHEMBL23234921 | 0.77 | PPIA (0.35) | ALDH1A1TP53MAPTSMN1; SMN2NPC1 | |
| SCHEMBL21543187 | 0.76 | GRM2 (0.46) | DHODHSMN1; SMN2MBNL1NPC1RAB9A | |
| SCHEMBL23234580 | 0.74 | NTRK1 (0.41) | MAPTNPC1RAB9AADORA2AADORA3 | |
| SCHEMBL31745211 | 0.73 | KHK (0.49) | ALDH1A1MBNL1ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-09 | — | — | US | disclosed |
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3807276-A2 | KRAS G12C INHIBITORS ENCOMPASSING A PIPERAZINE RING AND USE THEREOF IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | ALDH1A1 3126/4885ALOX15 3098/4885KEAP1 134/4885 |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | ALDH1A1 3126/4885ALOX15 3098/4885KEAP1 134/4885 |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | ALDH1A1 4307/4885ALOX15 2973/4885KEAP1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.